Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$33.90 USD

33.90
742,184

+1.26 (3.86%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $33.88 -0.02 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Celgene (CELG) Poised for a Beat This Earnings Season?

by Zacks Equity Research

Celgene Corporation (CELG) is expected to beat estimates once again on the back of strong performance of key drug Revlimid.

    Zacks Equity Research

    Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y

    by Zacks Equity Research

    Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene.

      Zacks Equity Research

      Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss

      by Zacks Equity Research

      Agios (AGIO) posted wider-than-expected loss in the second quarter of 2017. Revenues also came below expectations. However, revenues increased significantly year-over-year.

        Zacks Equity Research

        4 Medical Product Stocks Likely to Top Q2 Earnings Estimates

        by Zacks Equity Research

        There are some powerful long-term tailwinds in the medical space.

          Zacks Equity Research

          Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More

          by Zacks Equity Research

          Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.

            Zacks Equity Research

            Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?

            by Zacks Equity Research

            Agios Pharmaceuticals (AGIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

              Zacks Equity Research

              Will Expenses Hit Envision Healthcare (EVHC) Q2 Earnings?

              by Zacks Equity Research

              Envision Healthcare's (EVHC) second-quarter earnings may suffer from high operating cost and low revenues from the ambulatory service unit.

                Zacks Equity Research

                Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session

                by Zacks Equity Research

                Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise over 5% on the day.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote

                  by Arpita Dutt

                  Companies like Gilead (GILD) topped expectations in the second quarter while Dynavax shot up on a positive FDA advisory panel vote.

                    Zacks Equity Research

                    Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View

                    by Zacks Equity Research

                    Celgene Corporation (CELG) beat earnings and revenue estimates in the second quarter and upped view.